|
JP2010534469A
(ja)
|
2007-07-25 |
2010-11-11 |
アストラゼネカ アクチボラグ |
Ｋｄｒ指向性標的化結合物質およびその使用
|
|
JO3375B1
(ar)
*
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
|
SG192673A1
(en)
|
2011-02-10 |
2013-09-30 |
Roche Glycart Ag |
Mutant interleukin-2 polypeptides
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
EP2785742B1
(en)
|
2011-11-02 |
2020-01-08 |
Apexigen, Inc. |
Anti-kdr antibodies and methods of use
|
|
CN103087192B
(zh)
*
|
2011-11-02 |
2015-02-04 |
埃派斯进有限公司 |
抗-kdr抗体和使用方法
|
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
US9475866B2
(en)
*
|
2012-09-12 |
2016-10-25 |
Neurimmune Holding Ag |
Human islet amyloid polypeptide (hIAPP) specific antibodies and uses thereof
|
|
PT3102595T
(pt)
|
2014-02-06 |
2019-01-11 |
Hoffmann La Roche |
Proteínas de fusão de interleucina-2 e suas utilizações
|
|
US20180193456A1
(en)
*
|
2015-06-30 |
2018-07-12 |
Henlius Biotech Co., Ltd. |
Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies
|
|
TWI767915B
(zh)
|
2016-06-27 |
2022-06-21 |
加州大學董事會 |
Ror-1與btk拮抗劑的組合
|
|
WO2018148447A1
(en)
*
|
2017-02-08 |
2018-08-16 |
Adimab, Llc |
Antibody heavy chain variable domains targeting the nkg2d receptor
|
|
AU2018219887B2
(en)
|
2017-02-08 |
2024-08-15 |
Dragonfly Therapeutics, LLC |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
CN110944661A
(zh)
|
2017-02-20 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
结合her2、nkg2d和cd16的蛋白质
|
|
PE20250933A1
(es)
|
2017-03-14 |
2025-04-02 |
Five Prime Therapeutics Inc |
Anticuerpos de union a vista a ph acido
|
|
WO2019084057A2
(en)
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
|
|
KR20200069364A
(ko)
|
2017-10-24 |
2020-06-16 |
마젠타 테라퓨틱스 인코포레이티드 |
Cd117+ 세포의 고갈을 위한 조성물 및 방법
|
|
WO2019084053A1
(en)
*
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
|
|
BR112020015994A2
(pt)
|
2018-02-08 |
2020-12-15 |
Dragonfly Therapeutics, Inc. |
Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
|
|
CA3237846A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
WO2019164930A1
(en)
|
2018-02-20 |
2019-08-29 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
|
|
BR112020019083A2
(pt)
|
2018-03-21 |
2020-12-29 |
Five Prime Therapeutics, Inc. |
Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
|
|
PE20210687A1
(es)
|
2018-07-11 |
2021-04-08 |
Bristol Myers Squibb Co |
Anticuerpos de union a vista a ph acido
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
KR102835308B1
(ko)
|
2018-08-08 |
2025-07-21 |
드래곤플라이 쎄라퓨틱스, 인크. |
Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
|
|
EP3833392A4
(en)
|
2018-08-08 |
2022-05-18 |
Dragonfly Therapeutics, Inc. |
MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
|
|
JP7512394B2
(ja)
|
2020-05-06 |
2024-07-08 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｎｋｇ２ｄ、ｃｄ１６及びｃｌｅｃ１２ａに結合するタンパク質
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
EP4376859A4
(en)
|
2021-07-29 |
2025-07-30 |
Sonoma Biotherapeutics Inc |
SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
|